Börje Ljungberg1, Laurence Albiges2, Yasmin Abu-Ghanem3, Jens Bedke4, Umberto Capitanio5, Saeed Dabestani6, Sergio Fernández-Pello7, Rachel H Giles8, Fabian Hofmann9, Milan Hora10, Tobias Klatte11, Teele Kuusk12, Thomas B Lam13, Lorenzo Marconi14, Thomas Powles15, Rana Tahbaz11, Alessandro Volpe16, Axel Bex17. 1. Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden. Electronic address: borje.ljungberg@umu.se. 2. Department of Cancer Medicine, Gustave Roussy, Université Paris-Saclay, Villejuif, France. 3. Department of Urology, Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel. 4. Department of Urology, University Hospital Tuebingen, Tuebingen, Germany; German Cancer Consortium and German Cancer Research Center, Heidelberg, Germany. 5. Department of Urology, San Raffaele Scientific Institute, Milan, Italy; Division of Experimental Oncology/Unit of Urology, URI, IRCCS San Raffaele Hospital, Milan, Italy. 6. Department of Translational Medicine, Division of Urological Cancers, Lund University, Malmö, Sweden. 7. Department of Urology, Cabueñes University Hospital, Gijón, Spain. 8. International Kidney Cancer Coalition, Duivendrecht, The Netherlands. 9. Department of Urology, Sunderby Sjukhus, Umeå University, Luleå, Sweden. 10. Department of Urology, University Hospital Pilsen and Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic. 11. Department of Urology, Charité-Universitätsmedizin Berlin, Berlin, Germany. 12. Department of Urology, Darent Valley Hospital, Dartford and Gravesham NHS Trust, Dartford, UK. 13. Academic Urology Unit, University of Aberdeen, Aberdeen, UK; Department of Urology, Aberdeen Royal Infirmary, Aberdeen, UK. 14. Department of Urology, Coimbra University Hospital, Coimbra, Portugal. 15. The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK. 16. Department of Urology, University of Eastern Piedmont, Maggiore della Carità Hospital, Novara, Italy. 17. The Royal Free London NHS Foundation Trust, London, UK; UCL Division of Surgery and Interventional Science, London, UK; Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Abstract
CONTEXT: The European Association of Urology (EAU) Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC. OBJECTIVE: To present a summary of the 2022 RCC guideline, which is based on a standardised methodology including systematic reviews (SRs) and provides transparent and reliable evidence for the management of RCC. EVIDENCE ACQUISITION: For the 2022 update, a new literature search was carried out with a cutoff date of May 28, 2021, covering the Medline, EMBASE, and Cochrane databases. The data search focused on randomised controlled trials (RCTs) and retrospective or controlled comparator-arm studies, SRs, and meta-analyses. Evidence synthesis was conducted using modified GRADE criteria as outlined for all the EAU guidelines. EVIDENCE SYNTHESIS: All chapters of the RCC guideline were updated on the basis of a structured literature assessment, and clinical practice recommendations were developed. The majority of the studies included were retrospective with matched or unmatched cohorts and were based on single- or multi-institution data or national registries. The exception was systemic treatment of metastatic RCC, for which there are several large RCTs, resulting in recommendations that are based on higher levels of evidence. CONCLUSIONS: The 2022 RCC guidelines have been updated by a multidisciplinary panel of experts using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2022. PATIENT SUMMARY: The European Association of Urology panel for guidelines on kidney cancer has thoroughly evaluated the research data available to establish up-to-date international standards for the care of patients with kidney cancer.
CONTEXT: The European Association of Urology (EAU) Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC. OBJECTIVE: To present a summary of the 2022 RCC guideline, which is based on a standardised methodology including systematic reviews (SRs) and provides transparent and reliable evidence for the management of RCC. EVIDENCE ACQUISITION: For the 2022 update, a new literature search was carried out with a cutoff date of May 28, 2021, covering the Medline, EMBASE, and Cochrane databases. The data search focused on randomised controlled trials (RCTs) and retrospective or controlled comparator-arm studies, SRs, and meta-analyses. Evidence synthesis was conducted using modified GRADE criteria as outlined for all the EAU guidelines. EVIDENCE SYNTHESIS: All chapters of the RCC guideline were updated on the basis of a structured literature assessment, and clinical practice recommendations were developed. The majority of the studies included were retrospective with matched or unmatched cohorts and were based on single- or multi-institution data or national registries. The exception was systemic treatment of metastatic RCC, for which there are several large RCTs, resulting in recommendations that are based on higher levels of evidence. CONCLUSIONS: The 2022 RCC guidelines have been updated by a multidisciplinary panel of experts using the highest methodological standards. These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2022. PATIENT SUMMARY: The European Association of Urology panel for guidelines on kidney cancer has thoroughly evaluated the research data available to establish up-to-date international standards for the care of patients with kidney cancer.
Authors: Liliana Vartolomei; Andrei Cotruș; Camelia Stanciu; Cristian Delcea; Marco Tozzi; Elena Lievore; Felice Crocetto; Francesco Del Giudice; Giuseppe Lucarelli; Matteo Muto; Matteo Ferro Journal: J Clin Med Date: 2022-07-07 Impact factor: 4.964